arvelle triangle

BRINGING INNOVATIVE
TREATMENTS TO PATIENTS
SUFFERING FROM
CNS DISORDERS

CENOBAMATE

Cenobamate (YKP3089) was discovered by SK Biopharmaceuticals and SK life science and is being investigated for the potential treatment of partial-onset seizures (also known as “focal seizures”) in adult patients.

Global trials for adults with partial-onset seizures are ongoing to evaluate cenobamate safety. An additional clinical trial is investigating cenobamate safety and efficacy for another form of epilepsy in adult patients.

The U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application for cenobamate for the potential treatment of partial-onset seizures in adults in February 2019.

Cenobamate is not approved by the FDA, European Medicines Agency (EMA) or any other regulatory authorities. Safety and efficacy have not been established.

Mechanism
Of Action

Cenobamate’s mechanism of action is not fully understood, but it is believed to work through two separate mechanisms: enhancing inhibitory currents through positive modulation of GABA-A receptors and decreasing excitatory currents by inhibiting the persistent sodium current.

LEADERSHIP

Mark Altmeyer

MARK ALTMEYER

Founder, Chief Executive Officer

learn more +
Ilise Lombardo, MD

ILISE LOMBARDO, MD

Founder, Chief Medical Officer

learn more +
Gregory Weinhoff, MD

GREGORY WEINHOFF, MD

Founder, Consultant

learn more +

INVESTORS

logo nova
logo lsp
logo brv
logo f-prime
logo hig
logo andera
logo kb investment

PARTNERS

logo sk life science
logo sk biopharmaceuticals

PRESS

2019

Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe

  • Arvelle Therapeutics GmbH to provide SK Biopharmaceuticals an upfront payment of $100 million with future milestone potential of up to $430 million
  • A new CNS-focused company, Arvelle received one of the largest initial financing commitments for a European-focused biopharmaceutical company from a global syndicate which includes NovaQuest Capital Management, Life Sciences Partners (LSP), BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners
  • Global industry leader Mark Altmeyer named Arvelle President and CEO
  • Arvelle intends to file a Marketing Authorization Application (MAA) for cenobamate for partial-onset seizures in adults
read more ›

CONTACT

(888) 317-1041

Switzerland:
Baarerstasse 14
6300 Zug
Switzerland
×
Mark Altmeyer

MARK ALTMEYER

Founder, Chief Executive Officer

Mr. Altmeyer is a Founder, Board Member and the Chief Executive Officer of Arvelle. He has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system (CNS) disorders. He was previously President and Chief Commercial Officer at Axovant.

Prior to that Mark was Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led a team of 1,700 employees and helped grow the company’s revenue from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit. Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.



×
×
Ilise Lombardo, MD

ILISE LOMBARDO, MD

Founder, Chief Medical Officer

llise Lombardo, MD is a Founder and the Chief Medical Officer of Arvelle. Prior to that she was Chief Medical Officer at Axovant. She has 15 years of experience leading clinical development and medical affairs programs across multiple therapeutic areas including neurological and psychiatric disorders. Dr. Lombardo has successfully managed clinical development and strategy, regulatory authority approval, and post-marketing activities.

Previously, she was Vice President, Clinical Development and Medical Affairs, at FORUM Pharmaceuticals. Dr. Lombardo also previously led a multitherapeutic Medical Affairs group and development teams at Pfizer. She is a trained psychiatrist and has worked in academic research and clinical practice. Prior to entering the pharmaceutical industry, she was an Assistant Professor of Clinical Research at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute. Dr. Lombardo received an M.D. from Yale University, an M.Phil. from the University of Cambridge, and an A.B. from Brown University.

She completed a research fellowship in molecular biology at Yale University and the University of Cambridge and completed her internship and residency in psychiatry as well as a four-year post-doctoral fellowship in molecular neuroimaging at Columbia University College of Physicians and Surgeons.



×
×
Gregory Weinhoff, MD

GREGORY WEINHOFF, MD

Founder, Consultant

Gregory Weinhoff, MD is a Founder, Board Member and consultant to Arvelle. He currently serves as Chief Financial Officer of Axovant Sciences. He has more than 20 years of experience in healthcare finance and operations as a venture capital investor and operating executive. Previously, Dr. Weinhoff was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across biotechnology, diagnostics, medical devices and healthcare services.

He was the founding Chief Executive Officer of Amicus Therapeutics and subsequently served on the company’s board of directors. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co. Dr. Weinhoff received an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School (Baker Scholar), and an A.B. in economics from Harvard College.



×